Hormonal
Obesity pharmacotherapy (GLP-1/GIP agonists) reduces body weight with minimal loss of lean mass and improves cardiovascular outcomes, potentially mitigating the adverse effects of intermittent fasting.
If you are considering obesity pharmacotherapy (like GLP-1 agonists), know that it can lead to significant weight loss (up to 21% in some trials) with minimal loss of muscle mass, which is a key advantage over intermittent fasting. It also reduces cardiovascular risk. However, long-term safety is still being studied, and combining it with lifestyle changes (diet and exercise) is recommended for the best outcomes.
treatment with tirzepatide, liraglutide or semaglutide reduces body weight with small effects on lean mass... Obesity pharmacotherapy reduces food intake and enhances satiety without the need to alter meal timing... Overweight or obesity patients without T2D but with preexisting CVD experience a marked decrease in the incidence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke while on semaglutide treatment
Why this rating
Based on large-scale clinical trials (e.g., SURMOUNT-3, semaglutide trials) showing significant weight loss and cardiovascular benefits.
Source
A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Aristides G. Eliopoulos et al. · Frontiers in Nutrition · 2025
DOI 10.3389/fnut.2025.1524125
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →